医学临床研究
   Jul. 15, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2020, Vol. 37 Issue (2): 199-202    DOI: 10.3969/j.issn.1671-7171.2020.02.012
Current Issue | Archive | Adv Search |
Effect of Magnesium Isoglycate Combined with Ademetionine Succinate on Liver Function and Prognosis after Interventional Therapy for Primary Liver Cancer
CHEN Hong-wei, YANG Sun-hu
General Surgery Department of the Ninth People's Hospital of Shanghai, Shanghai 201999
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To explore the effect of magnesium isoglycate combined with ademetionine succinate on liver function and prognosis after interventional therapy for primary liver cancer.【Methods】One hundred and eighty patients with primary liver cancer who were treated in our hospital from August 2014 to may 2017 were selected as the study objects. According to the different schemes of liver protection after TACE, it was divided into two groups: group A (reduced glutathione + magnesium isoglycate injection) and group B (magnesium isoglycate + adenosylmethionine succinate). Serum ALT, AST, DBIL and TBIL levels were compared between the two groups. The adverse reactions of the two groups were observed to analyze the prognostic factors of patients with primary liver cancer.【Results】After treatment, the levels of ALT, AST, DBIL and TBIL in the two groups were significantly higher than those before treatment (P<0.05). The levels of ALT, AST, DBIL and TBIL in the group B were lower than those in the group A (P<0.05). The incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group A were 26.44%, 25.29%, 20.69% and 2.30% respectively; the incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group B were 24.73%, 20.43%, 16.13% and 2.15%, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The mean survival time of the group A was 27.40 (95% CI: 25.22~29.59) months, and that of the group B was 30.27 (95% CI: 28.40~32.14) months.There was significant difference between the two groups in the 3a survival time (P<0.05).Cox single factor and multi factor analysis showed that tumor number, vascular invasion and liver protection were closely related to the prognosis of patients with primary liver cancer.【Conclusion】Magnesium isoglycate combined with ademetionine succinate can improve the liver function and prognosis of patients with primary liver cancer after TACE treatment, which is worthy of clinical promotion.
Key wordsLiver Neoplasms      Embolization,Therapeutic      Glycyrrhizin/MT     
Received: 19 May 2019     
PACS:  R735.7  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
CHEN Hong-wei
YANG Sun-hu
Cite this article:   
CHEN Hong-wei,YANG Sun-hu. Effect of Magnesium Isoglycate Combined with Ademetionine Succinate on Liver Function and Prognosis after Interventional Therapy for Primary Liver Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(2): 199-202.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.02.012     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I2/199
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech